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Multi-variate curve resolution (MCR)We have employed for the ﬁrst time Raman spectroscopic imaging along with multi-variate curve resolution
(MCR) analysis to investigate in real time and in-situ the dissolution mechanisms that underpin amorphous
solid dispersions, with data being collected directly from the dosage form itself. We have also employed a
novel rotating disk dissolution rate (RDDR) methodology to track, through the use of high-performance liquid
chromatography (HPLC), the dissolution trends of both drug and polymer simultaneously in multi-component
systems. Two formulations of poorly water-soluble felodipine in a polymeric matrix of copovidone VA64
which have different drug loadings of 5% and 50% w/wwere used asmodels with the aim of studying the effects
of increasing the amount of active ingredient on the dissolution performance. It was found that felodipine
and copovidone in the 5% dispersion dissolvewith the same dissolution rate and that no Raman spectral changes
accompanied the dissolution, indicating that the two components dissolve as single entity, whose behaviour
is dominated by water-soluble copovidone. For the 50% drug-loaded dispersion, partial RDDR values of
both felodipine and copovidone were found to be extremely low. MCR Raman maps along with classical
Raman/X-ray powder diffraction (XRPD) characterisation revealed that after an initial loss of copovidone from
the extrudate the drug re-crystallises, pointing to a release dynamics dependent on the low water solubility
and high hydrophobicity of felodipine. Raman imaging revealed different rates of transition from amorphous
to crystalline felodipine at different locations within the dosage form.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
A high number of new chemical entities emerging from the drug de-
velopment process show pharmacological activity, but at the same time
are characterised by poor dissolution and solubility proﬁles [1]. As a re-
sult, there is a strong push to develop innovative formulations for the
delivery of such compounds so that the desired oral bioavailability
and pharmacological effects are achieved. An increasingly popular
class of formulation is represented by amorphous solid dispersions,
which are prepared by co-processing the drug and a water-soluble or
water-swellable polymeric carrier, commonly via spray drying or hot
melt extrusion [2,3]. The resultant dispersion, as widely demonstrated
for several poorly soluble compounds, has an improved dissolution
proﬁle and consequently bioavailability compared to the pure drug
[4]. This is attributed to the fact that the drug within the dispersion ex-
ists in the amorphous form, which gives a higher dissolution rate thanC. Burley).
Inc. This is an open access article uthe corresponding crystalline form, and also due to the presence of the
water-soluble polymer [5,6].
One of the key challenges for deploying amorphous solid dispersions
in real-world formulations is the understanding of the dissolution per-
formance. Although this is very relevant, due to the fact that the disso-
lution performance limits the in vivo efﬁcacy, relatively few studies
have been conducted to investigate the dissolution mechanisms that
underpin these systems. As reported by Craig, [7] the dissolutionmech-
anism of amorphous solid dispersions is characterised by a number of
critical processes, which primarily depend on the chemical nature of
the components and on the drug-to-polymer ratio. In relation to these
parameters, Craig classiﬁed the drug release from amorphous solid dis-
persions as polymer-controlled or drug-controlled. It has been demon-
strated that the re-crystallisation of the drug either in the solid state
or after precipitation in solution, [8,9] the formation of nano- and
micro-particles during the dissolution [10] and also the behaviour of
the polymer itself, [11] strongly contribute to the ﬁnal dissolution
performance. Amorphous solid dispersion dissolution mechanisms are
extremely difﬁcult to de-convolute due to several processes occurring
simultaneously.nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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of USP dissolution apparatuses [12] do not offer any chemical or
spatially-resolved information on potential changes of the solid form
(e.g. from amorphous to crystalline, polymorphic transformations or
formation of hydrate states) during the dissolution, since the data are
collected from the solution, rather than directly from the solid dosage
form itself. Given the limitations of the conventional dissolution appara-
tuses, innovative methods have been developed in an attempt to pro-
vide a more complete picture of the drug release. Such methods have
included mid-IR, [13,14] near-IR [15,16] and magnetic resonance imag-
ing (MRI) [8,17]. Mid-IR and near-IR provide chemical information, but
also have a signiﬁcant drawback; they are very sensitive towaterwhich
clearly limits the use of these techniques in aqueous environments. MRI
is attractive as it can offer three-dimensional information, however it
provides little chemical speciﬁcity.
Raman spectroscopy, theoretically, offers advantages/complemen-
tarities compared to these techniques. It provides chemically detailed
and two-dimensional spatial information (‘hyper-spectral data’, one
spectrum per pixel) and is able to readily differentiate between amor-
phous and crystalline solid forms [18,19]. These properties are signiﬁ-
cant since the chemical and physical forms of the drug can change
during the course of the dissolution test [8,9,14]. Moreover, with respect
to mid-IR and near-IR, Raman spectroscopy is relatively insensitive to
water [20]. Raman spectroscopy is therefore an appropriate technique
to investigate how the solid state properties of the drug affect its release
and for this reasonwas employed in thiswork to understand the perfor-
mance of amorphous solid dispersions during dissolution in aqueous
media.
An amorphous solid dispersion of felodipine, the active ingredient, in
a polymericmatrix of copovidoneVA64,was used asmodel formulation.
Felodipine is an antihypertensive drug, characterised by high permeabil-
ity and low water solubility (lower than 0.5 mg/lt) [21]. Copovidone
VA64 is a highly water-soluble polymer (solubility higher than
100 mg/lt), [22] recognised as a chemical analogue of polyvinylpyrroli-
done (PVP). In previous studies, PVP and copovidone VA64 have been
successfully used to prepare one-phase amorphous felodipine binary
mixtures over a range of composition (0–70% drug loading), showing
the ability to inhibit re-crystallisation and to increase the dissolution
rate of poorly soluble felodipine [23–27]. The physical mixture of
crystalline felodipine and copovidone VA64 has been shown instead
to have a small increase in dissolution rate when compared to pure
crystalline felodipine, further demonstrating how the physical state
of the active ingredient (e.g. amorphous vs. crystalline) affects the
whole dissolution performance regardless the presence or absence
of the polymer in the formulation [8]. This work follows on from
the recent paper by Langham et al., where the use of a combined
spectrophotometric and magnetic resonance imaging technique to
investigate the dissolution mechanisms of felodipine–copovidone
spray-dried amorphous solid dispersions was described [8]. It was
found that the dissolution behaviour of the high drug-loaded amor-
phous solid dispersions is governed by the low aqueous solubility of
felodipine and by the re-crystallisation (conﬁrmed by off-line XRPD)
of the drug.
In the present work, we investigated formulations which have dif-
ferent drug loadings (5% and 50%w/w), with the aim of studying the ef-
fects of increasing the amount of active ingredient on the dissolution
performance. Two different approaches were employed to probe the
dissolution performance of amorphous solid dispersions. The ﬁrst used
Raman spectroscopy and the second uses a rotating disk dissolution
rate (RDDR) test. Our RDDR method, with respect to conventional
intrinsic dissolution rate (IDR) test described in the USP and in the
European Pharmacopoeia, [12,28] employs HPLC to separate the drug
from the polymer and ultimately allows us tomeasure the performance
in aqueous media of multi-component systems.
The aim of this work is to investigate whether Raman spectroscopy
provides additional chemical and spatial information regarding thedissolution mechanisms that underpin amorphous solid dispersions,
used in conjunction with RDDR dissolution test.
2. Materials and methods
2.1. Preparation of amorphous felodipine and extrudate solid dispersions
The amorphous form of felodipinewas obtained by heating the drug
as received (AstraZeneca, Macclesﬁeld, United Kingdom) in the oven to
160 °C and, after melting, cooling back to room temperature. Visual in-
spection and Raman spectroscopy conﬁrmed the formation of the amor-
phous form and the absence of crystalline material within the detection
limits (ca. 0.5% or better). 5% and 50% drug-loaded amorphous solid dis-
persions of felodipine in copovidone (BASF, Ludwigshafen, Germany)
were prepared using a co-rotating twin-screw extruder (Thermo Scien-
tiﬁc HAAKEMiniLab II). Felodipine and copovidone were pre-mixed for
20 min in a Turbula T2F mixer (Willy A. Bachofen AG Mashinefabrik).
The extruder was manually fed with the physical mixture. The screw
speedwas set to 150 rpmand the temperature to 160 °C. The extrudates
with spaghetti shape were then collected, cooled to room temperature
and manually milled to ﬁne powder. X-ray powder diffraction con-
ﬁrmed the formation of the amorphous solid dispersion and the absence
of crystalline material (Figure S1).
2.2. X-ray powder diffraction (XRPD)
XRPD patternswere obtained using a PANalytical CubiX PRO diffrac-
tometer. Samples were exposed to Cu-Kα radiation at a voltage of 45 kV
and a current of 40 mA. After being smeared onto the holder, samples
were scanned from 2° to 40° 2θ, with a step size of 0.02° 2θ.
2.3. Rotating disk dissolution rate (RDDR)
RDDR testing was carried on using the rotating disk system, also
known as ‘Woods apparatus’. The die cavity has a diameter of 8 mm
with subsequent exposed sample surface area of 0.5 cm2. About
250 mg of extrudate powder was compressed under a compression
force of 2000 kg using a manual IR press (Specac). The experiment
was performed in a Sotax AT7 semi-automated dissolution bath
equipped with an automated sample collector. Compressed discs were
immersed in 500ml of deionised water at 37 °C (±0.5), at 100 rpm ro-
tational speed. The automated sample collector removed aliquots of
sample from the dissolution medium at regular time intervals over
120min. The sampleswere then analysed by reverse phase high perfor-
mance liquid chromatography (RP-HPLC). Both the experiments for 5
and 50% extrudateswere performed in triplicate. HPLC analysiswas car-
ried out using a Agilent 1100 with UV detection at 210 nm, equipped
with an Agilent PLRP-S 300 Å 3 μm 50 mm column (polystyrene/
divinylbenzene stationary phase). The ﬂow rate was set to 1.0 ml/min
and the temperature of the column was kept at 40 °C. A linear gradient
elution was used starting at 40% acetonitrile/60% deionised water and
ending at 90% acetonitrile/10% deionisedwater after 3.5min,with chro-
matograms collected up to 5 min. A series of standard solutions of
felodipine and copovidone were prepared to generate a calibration
curve covering the concentration range of dissolved sample. The partial
RDDR of both drug and polymer was calculated using linear regression
analysis [12,28]. The partial RDDR of the substance tested was deter-
mined from the slope of the regression line.
2.4. Raman spectroscopy
We investigated the dissolution performance of compressed
extrudate powder. Spherical compacts with a diameter of 5 mm and a
weight of 50 mg were prepared with a manual IR press (Specac) using
a compression force of ca. 20 kN. The dissolution test was performed
in a ﬂow cell, which is illustrated in Figure S2. Deionised water was
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ﬂow cell was placed under the objective of the Raman microscope and
data were collected as function of time using a Horiba LabRAMHR con-
focal microscope/spectrometer. The system has an automated xyz stage
(Märzhäuser) for mapping. In all the experiments, a near-IR laser
(785 nm) of 250 mW power was employed. Spectra were acquired
using a 50 × objective and a 300 μm confocal hole. A 600 lines/mm
rotatable diffraction grating along a path length of 800 mm was used
to simultaneously scan a range of frequencies. Raman spectra were
collected using a SYNAPSE CCD detector (1024 pixels). During the
dissolution experiment, before each map being acquired, the z-axis
position of the sample was adjusted to maximise the Raman signal.
For both formulations (5% and 50% felodipine), spectra were obtained
mapping an area of 500 × 500 μm with a grid spacing of 50 μm along
both x-axis and y-axis, a total of 121 spectra for map. As each individual
spectrum was collected for 1 s, repeated once in order to automatically
remove the cosmic rays, the whole map required only 5 min. For the 5%
extrudate compact, eight maps were acquired across a 70 minute time
frame in the spectral range from 1100 to 1750 cm−1 (ﬁnger print
region). For the 50% extrudate compact, eight maps were acquired
over 1705 min (28 h25) in the phonon-mode (30–400 cm−1) and
ﬁnger print (1100–1750 cm−1) regions using a ﬁxed grating to allow
relatively rapid mapping. In the latter case, the phonon-mode range
was also scanned because it is extremely sensitive to the different
solid forms (amorphous, crystalline, etc.) and therefore the potential
drug re-crystallisation can be readily detected [18,19]. All the spectra
from each map were integrated to produce a single averaged spectrum
corresponding to each time point. In this way, it was possible to deter-
mine any spectral changes occurring during the dissolution test.
To obtain spatially-resolved information from the 50% extrudate
compact, the dissolution experiment was repeated increasing signiﬁ-
cantly the spatial resolution. Seven maps were acquired over 1705 min
(28 h25) in the spectral range between 1100 and 1750 cm−1, across a
500 × 1000 μm area at a grid spacing of 15 μm along the x-axis, and
30 μmalong the y-axis, a total of 1156 spectra permap. As the data acqui-
sition time was 2 s for each spectrum, repeated once, each map requiredFig. 1. Optical images taken through the dissolution experimen1 h and 30 min for acquisition. False colour maps were generated using
multi-variate curve resolution (MCR). A single data matrix, comprising
all the spectra collected across the entire dissolution experiment (8092
spectra), was produced in order to probe changes as a function of both
xy-position and time. Numerical codes for statistical analyses were writ-
ten in the ‘R’ language, which is open-source and freely available [29].
Data were scaled prior to analysis and plotting using variance scaling
and mean centering standard methods, as per standard practice [20] to
reduce the effect of variability in Raman scattering efﬁciency. For multi-
variate curve resolution analysis, the ‘ALS-MCR’ module (alternating
least-squares algorithm) was employed, while hierarchical agglomera-
tive clustering is part of the standard package in R. All numerical routines
along with the raw data are included in the supplementary material for
information and reference.
2.5. Optical imaging
Photographic images of the compact during the dissolution were
taken at regular time intervals using a CoolSNAP-Pro CF camera
(Media Cybernetics) equipped with a Nikon AF Micro NIKKOR 60 mm
lens. The same experimental setup described in the previous section
was used, with the ﬂow cell placed under the camera instead of the
Raman microscope.
3. Results and discussion
3.1. Optical imaging
Before commencing a full discussion of the RDDR and Raman data, it
is important to observe the optical images taken through the dissolution
experiment for the 5% and 50% drug-loaded compacts (Fig. 1a and b).
Prior to the dissolution test, both formulations appear similar, being yel-
lowish compacts. It is important to notice the different experimental
time-scales used for the two formulations. The 5% extrudate dissolution
experiment was carried out for 80 min after which time the images
show that the compact is completely dissolved. For the 50% drug-t of the 5% extrudate (a) and 50% extrudate (b) compacts.
56 F. Tres et al. / Journal of Controlled Release 188 (2014) 53–60loaded formulation, the time-scale was signiﬁcantly longer. In total, the
compact was observed in the ﬂow cell for 1705 min, remaining intact
even after the end of this period. An in depth observation of the images
from the 50% extrudate shows that the compact swells and increases in
size during the ﬁrst 316 min, then slightly reduces and remains intact
until the end of the experiment. This suggests that the initial hydration
leads to swelling of the compact rather than to dissolution/erosion, due
to the high content of poorly soluble felodipine in the extrudate (images
until 316 min). This behaviour was previously described by Langham
et al [8]. In Fig. 7 of their paper, they reported MRI sequences showing
that the 50% felodipine-loaded spray-dried material swells as a result
of water ingress from the dissolution medium. The visual observation
of the optical images relative to the 50% extrudate is conﬁrmed by the
kinetic trend generated by counting the number of pixels of the com-
pact during the dissolution test (Figure S3). The trend is characterised
by an increase in pixel number until 316 min, which corresponds to
the observed increase in the compact size. Following this, the number
of pixels decreases with the rate of decrease falling to near-zero
between 1093 and 1705min, conﬁrming that the size of the compact re-
duces after an initial swelling. The reduction of the compact size after an
initial swelling was not previously seen in the MRI images reported by
Langham et al [8]. This change in behaviour may be related to the differ-
ent conditions during preparation via hot melt extrusion compared
to spray drying (e.g. high temperatures, absence of solvents, formulation
bulk density, etc) whichmay affect the ﬁnal physico-chemical properties
of amorphous solid dispersions and thus their performance in aqueous
media.
3.2. Rotating disk dissolution rate (RDDR)
The intrinsic dissolution rate (IDR) test has been widely used
in biopharmaceutics formeasuring the dissolution rate of pure active in-
gredients [30,31]. It is an important biopharmaceutics screening tool,
and requires far less material than a traditional dissolution test. IDR
measurements yield a dissolution rate normalised to the exposed
surface area of thematerial. Formally, IDR applies only to pure drug sub-
stances [12]. Here we extend the IDR concept to formulations. By anal-
ogy with disk IDR, we deﬁne a ‘rotating disc dissolution rate’ RDDR.
By simply coupling an IDR apparatus to a HPLC system, the partial
RDDR of both the pure drug substance and the excipients (in thepresent
case copovidone) can bemeasured and compared for different formula-
tions. The partial RDDR for the drug and polymer in the different
formulations are shown below to provide valuable information on the
mechanism of drug release.
The dissolution rate values for the 5% and 50% drug-loaded formula-
tions are summarised in Table 1. The dissolution proﬁles can be
inspected in Figure S4 of the supplementary information. Partial RDDR
was calculated using the ﬁrst 20 minute time period, where the trend
is relatively linear, in accordance with USP procedures [12]. Looking at
the formulation with 5% drug loading, the partial RDDR value for
felodipine is 0.17 mg/min/cm2, while the partial RDDR for copovidone
is 3.10 mg/min/cm2. The intrinsic dissolution rate value of pure crystal-
line felodipine has been previously found to be 0.00064 mg/min/cm2 inTable 1
Partial RDDR values of felodipine and copovidone for the 5% and 50% extrudate formula-
tions. The index of performancewas obtained dividing thepartial RDDR value of felodipine
by the total RDDR value of formulation (felodipine plus copovidone) and then normalising
by the felodipine mass fraction.
RDDR (mg/min/cm2)
Time Felodipine Copovidone Total Index of
performancea
5% extrudate b20 min 0.17 (±0.02) 3.10 (±0.43) 3.26 1.0
50% extrudate b20 min 0.01 (±0.01) 0.25 (±0.01) 0.26 0.07
a Index of performance = (Partial RDDR felodipine / Total RDDR) / drugmass fraction.pH 6.5 FaSSIF medium, so in comparison the 5% extrudate exhibits
approximately a 265 fold increase in dissolution rate [32]. The signiﬁ-
cant improvement in dissolution is in agreement with literature
on felodipine amorphous solid dispersions [27,33]. The dissolution
rate of the polymer allows calculation of an index of performance of
the formulation which essentially shows how the two components of
the amorphous solid dispersion behave during the dissolution process.
The equation to calculate the index of performance is reported in
Table 1. The index of performance for the low drug-loaded extrudate
results in a value of 1, indicating that felodipine and copovidone have
the same dissolution trend and thus they effectively dissolve as single
entity, the molecular dispersion of felodipine in copovidone. Given the
very low solubility of felodipine, the release of the 5% extrudate is clear-
ly dependent on the high water solubility of the polymer.
Turning now to the formulation with high drug loading, it is imme-
diately evident that both felodipine and copovidone have partial RDDR
values signiﬁcantly lower when compared to those calculated for the
5% extrudate (Table 1). The index of performance is also very
low (0.07), indicating that the dissolution rates of felodipine and
copovidone are in this case very different, suggesting that the two com-
ponents of the formulation are not behaving as a single entity but as two
separate components. Compared to the IDR value of pure extruded
copovidone (5.20 mg/min/cm2 in pH 6.8 blank FaSSIF medium,
Figure S4), copovidone present in the 50% extrudate shows approxi-
mately a 21 fold decrease in dissolution rate. RDDR data suggest that
the drug release is felodipine-dependent, where low solubility in
water and high hydrophobicity of the drug contribute to decrease the
wettability and to slow the water uptake in the formulation.
Summarising, the 5% drug-loaded extrudate showed polymer-
dependent dissolution behaviour with felodipine dissolving simulta-
neously with copovidone. For the 50% extrudate, the rate of felodipine
release is considerably lower than that observed for the 5% drug-
loaded formulation. Although the RDDR test gives a comprehensive ex-
planation about the dissolution trend observed for the low drug-loaded
formulation, it does not clearly explainwhy felodipine shows a very low
dissolution rate for the 50% extrudate. To obtain a better understanding
of the chemical changes that occur during dissolution of the formula-
tion, Raman spectroscopic imagingwas used to interrogate the samples.
3.3. Raman spectroscopy
3.3.1. Dry raw materials spectra: visual observation
The Raman spectra of the rawmaterials are shown in Fig. 2a (ﬁnger
print) and 2b (phonon-mode). Starting with the pure components, it is
evident that the spectrum of felodipine is characterised by sharp bands
and a good signal/noise ratio, whereas the spectrum of copovidone
shows less-deﬁned bands. At ﬁrst approximation, the amorphous solid
dispersion spectra appear as a linear combination of melt quenched
felodipine (amorphous reference form) and copovidone. In the 5%
extrudate spectrum, copovidone bands are predominant, while in the
50% extrudate bands related to felodipine prevail. In the latter case
two slight shifts appear when comparing to the spectrum of melt
quenched felodipine: the band at 1209 cm−1 moves to a lower wave-
number, while the band at 1497 cm−1 appears at higher wavenumber.
These changes can be ascribed to the formation of molecular interac-
tions between the drug and the polymer coupledwithminor conforma-
tional changes, as has been previously reported for amorphous solid
dispersions of felodipine and PVP [11].
Turning now to the felodipine spectra, we can see signiﬁcant differ-
ences between the amorphous (melt quenched felodipine) and the
crystalline (felodipine as received) solid forms. Firstly, the bands of
the crystalline form appear more intense and sharper than those of
the amorphous form, due to the disorganised molecular environment
of the amorphous solid state. Furthermore, a detailed observation
highlights that the intra-molecular vibration bands at 1213, 1492
and 1645 cm−1 of the amorphous form slightly shift to higher
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Fig. 2. Finger print (a) and phonon-mode (b) regions of rawmaterials spectra and ﬁnger print (c) and phonon-mode (d) regions of the averaged spectra relative to the dissolution of the
50% extrudate compact, with reference spectra in red. Y-Axis offsets were employed for presentational purposes and differ between panels.
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molecular vibration, the two felodipine solid forms have different spec-
tra. The amorphous form spectrum is characterised by broad bands and
a continuous distribution of inter-molecular vibrations. In the crystal-
line form, sharp bands are present at 94 and 168 cm−1, due to the
quantised nature of the inter-molecular vibrations in the crystallinema-
terial. Thus, as reported in literature, [18,19] the phonon-mode region
represents an area of the Raman spectrumwhere it is possible to rapidly
distinguish between different solid forms.
3.3.2. Dissolution experiments
3.3.2.1. Averaged spectra: visual observation. Raman averaged spectra
for the 5% extrudate dissolution are presented in Figure S5. Examination
of the data does not reveal signiﬁcant changes in the spectra across
the entire period covered by these data (0–70 min), beyond a reduc-
tion in spectral intensity as the compact dissolves (as seen in the
optical images Fig. 1a). The ratio between the band of felodipine at
1650 cm−1 and that of copovidone at 1426 cm−1 is preserved through-
out the whole dissolution process. The Raman data essentially show
that felodipine and copovidone dissolve as a single entity rather than
as two separate components. This is in accordance with the RDDR
data, which illustrated that felodipine and copovidone dissolve with
the same rate. Therefore, it seems reasonable to suggest that the disso-
lution occurs from the molecular dispersion, with the overall behaviour
being dependent on the highly-soluble polymer.
Raman data of the 50% extrudate dissolution are shown in Fig. 2c
(ﬁnger print region) and d (phonon-mode region). Raman data show
that the spectrum does not change after 10 min (Fig. 2c, 10 min). Bands
relative to felodipine (1497 unit cm−1) and copovidone (1426 cm−1)
preserve the same ratio as in the spectrum of the compact ‘Dry’. Proceed-
ing with the analysis, after 65 min the intensity of copovidone band
at 1426 cm−1 appears to decrease in relation to that of felodipine at
1497 cm−1. A comparison with the ‘50% extrudate’ reference spectrum
reveals that the band at 1209 cm−1moves to slightly higherwavenumberand that at 1497 cm−1 shifts to lower wavenumber. Figure S6 presents
‘difference spectra’ obtained by subtracting each averaged spectrum cor-
responding to each time point from the averaged spectrum of the com-
pact ‘Dry’, which was used in this case as reference spectrum.
‘Difference spectra’ between 65 and 316 min are characterised by nega-
tive bands at 1213 and 1492 cm−1 which correspond to the observed
shifts in Fig. 2c. These spectral shifts, which were previously denoted in
the visual observation of the raw ingredients spectra (Fig. 2a), unambigu-
ously indicate a strong correlation with the melt quenched (amorphous)
felodipine spectrum. It is likely that the faster dissolution of copovidone
with respect to felodipine from the drug:polymer dispersion leads to a
build-upof felodipine-rich amorphousmaterial on the surface of the com-
pact. The second important change occurs at 522 min. It is immediately
obvious that the averaged spectrum, after 522 min, corresponds to the
crystalline form of felodipine. When compared to melt quenched
felodipine, intra-molecular bands at 1202, 1484 and 1642 cm−1 shift to
lower wavenumber as well as they appear more intense and sharper.
These spectral changes were previously seen in Fig. 2a, revealing the for-
mation of crystalline felodipine. In the phonon-mode region (Fig. 2d),
well-deﬁned bands appear at 94 and 168 cm−1 after 522min, essentially
conﬁrming that amorphous felodipine begins to re-crystallise by this
time-point.
3.3.2.2. Averaged spectra: hierarchical agglomerative clustering (HAC). In
this sectionwe describe the use of an objective statistical analysismeth-
od to validate our subjective interpretation of the Ramandata. HAC is an
automated method of cluster analysis which calculates a distance, also
called ‘degree of dissimilarity’, between datasets, [34] including
Raman spectra [19]. The dendrogram obtained applying HAC to the 21
datasets is shown in Fig. 3. It is immediately evident that the overall
structure of the dendrogram is governed by two branches: spectra rela-
tive to the dissolution of the 5% extrudate with the 5% extrudate
and copovidone reference spectra, and spectra relative to the dissolu-
tion of the 50% extrudate with the remaining reference spectra (‘50%
extrudate’, ‘Melt quenched felodipine’ and ‘Felodipine as received’).
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58 F. Tres et al. / Journal of Controlled Release 188 (2014) 53–60Startingwith the branch of the 5% extrudate (LHS of plot), it is clear that
all the spectra relative to the dissolution can be classiﬁed by only one
cluster, as they are characterised by a high degree of similarity. This
trend is in a good agreement with the visual inspection of the data. As
noted earlier (Figure S5), signiﬁcant changes were not observed in the
spectra collected during the dissolution of the 5% extrudate compact.
Turning now to the other portion of the dendrogram, that relative to
the high drug-loaded formulation (RHS of plot), the presence of three
main clusters is immediately apparent. The ﬁrst includes ‘50% extrudate
dry’ and ‘50% extrudate 10 mins’ spectra,which showhigh similarity for
the 50% extrudate reference. The second cluster includes spectra
collected between 65 and 361 min, with the reference spectrum of
melt quenched (amorphous) felodipine. The last cluster includes
spectra collected from 522 min until the end of the experiment along
with the reference crystalline form of felodipine. Again, HAC conﬁrms
the visual inspection of the data, further demonstrating that two
transformations occur during the dissolution of the high drug-loaded
extrudate. The ﬁrst involves the conversion, via dissolution of
copovidone, ofmixed extrudate into felodipine-rich amorphousmateri-
al on the surface of the compact, indeed spectra collected between 65
and 361 min showed high similarity for the melt quenched reference
form. The other is the re-crystallisation of the amorphous felodipine
after 522 min. The ﬁrst transformation clearly explains the extremely
low partial RDDR values observed during the dissolution of the
50% extrudate. Copovidone cannot drive the dissolution of felodipine
due to an insufﬁcient polymer to drug ratio, resulting in formation of
felodipine-rich hydrophobic amorphous areas on the compact surface.
The disruption of the drug–polymer molecular dispersion system
through loss of copovidone then induces the drug re-crystallisation.
We conclude by stating that HAC widely validated all our subjective
observations of Raman data, adding to them an objective and impartial
component.
3.3.2.3. Multi-variate curve resolution (MCR).Wenowdiscuss the spatial-
ly resolved images of the crystallisation event observed for felodipine
present in the high drug-loaded formulation. Raman maps of the 50%
extrudate compact, obtained byMCR analysis of all the spectra collected
across the entire dissolution test (8092 spectra), are presented in Fig. 4.MCR results can be presented as loadings which provide the spectral
phase of a speciﬁc component, and score plots that illustrate the spatial
distribution of the corresponding component. Three components were
required to deconvolute the mapped data. Comparison with the refer-
ence spectra unambiguously indicates that the ﬁrst component, MCR1,
can be associated with the extrudate and the second, MCR2, with the
crystalline form of felodipine. The excellent peak to peak correlation
between loadings and reference spectra conﬁrms the utility of MCR as
the statistical method to analyse spatial–temporal Raman data. MCR3
mostly picked up the background noise which characterises areas
where no compact is present. The score plots show that the extrudate
(MCR1) is homogenously distributed throughout the mapped compact
surface before immersion in water. The corresponding MCR2 score plot
indicated no traces of crystallinematerial in themapped area of the dry
compact. Then, the amount of crystalline felodipine (MCR2) rapidly in-
creases at the expense of the extrudate (MCR1) after 316min, and this is
reﬂected by the re-crystallisation kinetic shown in Fig. 5. It is interesting
to notice the complementarity of MCR1 and MCR2 score plots at 316
and 522 min, which denotes the coexistence of the extrudate and crys-
talline felodipine. Regions where the extrudate (MCR1) is present to its
maximumare indicated bywhite or red colour,while the corresponding
crystalline regions (MCR2) are characterised by blue colour, and vice
versa. The re-crystallisation of amorphous felodipine evidently occurs
at different rates in different regions of the compact surface, suggesting
that the crystal growth stage follows an initial stage of heterogeneous
nucleation. The nucleation/crystallisation process is likely linked with
loss of copovidone from the extrudate. It is well known that the poly-
meric carrier in amorphous solid dispersion formulations not only has
the function to improve the dissolution properties of poorly soluble
drugs, but also inhibits crystal growth of the amorphous form, via
antiplasticisation effect or hydrogen-bonding interactions between
drug and polymer [25]. It is therefore likely that loss of copovidone dur-
ing the ﬁrst 316 min, previously observed in the averaged Raman spec-
tra (Fig. 2c), promotes heterogeneous nucleation followed by
crystallisation of felodipine-rich amorphous material in the compact
surface.
At the end of the experiment, after 1705min, the residue of the com-
pact was recovered and analysed using Raman and XRPD. MCRmaps of
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Fig. 4. Raman maps of the 50% extrudate compact as function of time, generated by MCR analysis.
59F. Tres et al. / Journal of Controlled Release 188 (2014) 53–60the core (after breaking the compact into two parts) and surface are
presented in Figure S7. Two components were required in this case to
deconvolute the data, with the ﬁrst component (MCR1) corresponding
to amorphous felodipine and the second (MCR2) corresponding to crys-
talline felodipine. The score plots show that felodipine is predominantly
amorphous in the core, whereas in the surface is completely crystalline.0 500 1000 1500
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Fig. 5. Crystallisation kinetic generated by plotting the MCR component concentration in
each map as function of time.Raman data suggest that the crystallisation begins from the compact
surface exposed to water and propagates towards the core, where
only a little amount of crystalline drug was found. The XRPD pattern
of the compact after grinding it into powder can be seen in the supple-
mentary material (Figure S1). The pattern appears as a combination of
sharp bands, typical of the crystalline materials, and a broad halo
which characterises the amorphousmaterials. XRPD therefore indicates
that felodipine sampled from the entire compact after the dissolution
experiment is a mixture of crystalline and amorphous. This is in full
agreement with Raman results, which indicated a crystalline outer sec-
tion and an amorphous inner section of the compact.
4. Conclusions
We have demonstrated that Raman imaging offers an appropriate
method to investigate in real time the dissolution process and provides
additional spatial information regarding the dissolution mechanisms
that underpin amorphous solid dispersions, when compared to USP dis-
solution testing and classical Raman spectroscopy.We have successfully
employed a RDDR method which allows us to track the dissolution
proﬁles of both drug and polymer simultaneously and ultimately to
measure the dissolution performance in multi-component systems.
We have widely consolidated the previous ﬁndings described in
Langham et al. work, [8] by generating spatially-resolved MCR Raman
maps of the re-crystallisation of felodipine present in the 50% extrudate
formulation. MCR Raman maps showed that amorphous felodipine
crystallises at different rates in different regions of the compact surface,
60 F. Tres et al. / Journal of Controlled Release 188 (2014) 53–60indicating that crystallisation follows an initial stage of heterogeneous
nucleation. The re-crystallisation of felodipine leads to large variations
in the Raman spectrum and thus it is readily detectable. In particular
in the phonon-mode region, the spectrum of the crystalline form is
characterised by clear and sharp bands, while that of the amorphous
form by a broad halo. The nucleation/crystallisation process proceeds
from the surface towards the core and is likely linked to loss of
copovidone from the extrudate. For the 5% drug-loaded extrudate,
Raman spectroscopy did not show any signiﬁcant changes in the spectra
collected during the course of the dissolution test. This demonstrates
that felodipine and copovidone dissolve as a single entity, in accordance
with the RDDR data.5. Acknowledgements
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